RE:RE:RE:RE:Roche anti-TIGIT hope turns to TecentriqAll this is effectively related to ONCY given pelareorep's ability to convert an otherwise immunosuppressive tumor microenvironment (TME) into one that is favorable to combination immunotherapy, and do so synergistically.